Does Merck & Co. Inc. (MRK) Have Insiders Selling Shares?

As of Thursday close, Merck & Co. Inc.’s (NYSE:MRK) stock was up $2.84, moving up 3.19 percent to $92.00. The average number of shares traded per day over the past five days has been 16,869,779 shares. 5 times new highs have been achieved over the past 5 days, with a $7.37 gain in that time frame. In the last twenty days, the average volume was 12,686,915, while in the previous 50 days, it was 12,273,340.

Since last month, MRK stock retreated -1.95%. Shares of the company fell to $83.05 on 06/16/22, the lowest level in the past month. A 52-week high of $94.92 was reached on 05/23/22 after having rallying from a 52-week low of $70.89. Since the beginning of this year, MRK’s stock price has risen by 20.04% or $15.36, and marked a new high 22 times. However, the stock has declined by -3.08% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Merck & Co. Inc. (MRK) last reported insider trading activity 227 days ago on Nov 09. FRAZIER KENNETH C, the Executive Chair of the company, disposed of 663,881 shares for $82.26 on Nov 09. It resulted in a $54,611,362 divestment by the insider. Litchfield Caroline sold 18,335 shares at an average price of $91.00 on Nov 04. The insider now owns 24,114 shares following the transaction. On Nov 04, EVP&Pres, Merck Animal Heallth DeLuca Richard R. sold 29,782 shares at $90.40 apiece. The transaction was valued at $2,692,299.

Valuation Metrics

Right now, Merck & Co. Inc. (MRK) has a P/E ratio of about 16.78. The stock’s beta is 0.40. Besides these, the trailing price-to-sales (P/S) ratio of 4.32, the price-to-book (PB) ratio of 5.69, and the price-to-cash flow ratio of 38.44 may also be considered.

The latest dividend of $0.69 per share was paid out, remained unchanged from last year’s $0.69. On Tuesday November 30 2021, a $0.04 dividend increase was announced.

Financial Health

In the three months ended March 30, Merck & Co. Inc.’s quick ratio stood at 1.10, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.75, and the total debt-to-equity ratio was 0.78. On the profitability front, the trailing twelve-month gross margin is 71.10% percent. In the year ended March 30, operating margins totaled 28.90%. Based on annual data, MRK earned $35.08 billion in gross profit and brought in $48.7 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 15.50%. Return on equity (ROE) for the past 12 months was 38.30%.

In Merck & Co. Inc.’s quarter-end financial report for March 30, it reported total debt of $30.59 billion against cash and short-term investments of $372.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MRK’s revenue rose 24.03% to $12.07 billion during the quarter, while net income inched up to $15.9 billion. While analysts expected Merck & Co. Inc. to report $1.83 quarterly earnings, the actual figure was $2.14 per share, beating the consensus estimate by 16.90%. During the quarter, the company generated $6.74 billion in EBITDA. The liabilities of Merck & Co. Inc. were 65.72 billion at the end of its most recent quarter ended March 30, and its total debt was $31.79 billion. The value of shareholders’ equity is $2.53 billion.

Technical Picture

This quick technical analysis looks at Merck & Co. Inc.’s (MRK) price momentum. With a historical volatility rate of 30.00%, the RSI 9-day stood at 68.33% on 23 June.

With respect to its five-day moving average, the current Merck & Co. Inc. price is up by +8.71% percent or $7.37. At present, MRK shares trade -2.79% below its 20-day simple moving average and +13.72% percent above its 100-day simple moving average. However, the stock is currently trading approximately +6.20% above its SMA50 and +21.08% above its SMA200.

Stochastic coefficient K was 76.65% and Stochastic coefficient D was 51.87%, while ATR was 2.17. Given the Stochastic reading of 98.35% for the 14-day period, the RSI (14) reading has been calculated as 61.94%. As of today, the MACD Oscillator reading stands at 3.06, while the 14-day reading stands at 2.04.

Analyst Ratings

Merck & Co. Inc. (MRK) has been rated Overweight by analysts. According to 0 brokerage firms, MRK is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate Merck & Co. Inc. stock as buy, with 10 recommending it as overweight.

With a median target price of $97.00, the current consensus forecast for the stock is $85.00 – $115.00. Based on these forecasts, analysts predict Merck & Co. Inc. (MRK) will achieve an average price target of $98.21.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam